CDC Website CDC Website

To Join the NPIN community or

You are here

HIV/AIDS

Technical Assistance to Central Asian National HIV Programs to Achieve and Sustain HIV Epidemic Control under the President's Emergency Plan for AIDS Relief (PEPFAR)

Edith Jickling's picture

This NOFO is for technical assistance to the national HIV programs supported by the CDC Central Asia Regional office under PEPFAR. The technical assistance provider will pilot and evaluate new models of service delivery for 1) accelerating antiretroviral treatment (ART) scale up, adherence, and retention 2) HIV case finding and 3) harm reduction among Key Populations (KP) and PLHIV. Successful models of service delivery and electronic monitoring of patient care will be handed over, scaled up, and sustained by host country government by the end of the five year cooperative agreement.

Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages applications for the Global Infectious Disease (GID) Research Training Program from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of an LMIC institution to conduct infectious disease research.

AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF)

This notice solicits applications for the Ryan White HIV/AIDS Program (RWHAP) Part B AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF). The Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB), Division of State HIV/AIDS Programs (DSHAP) administers this program. ADAP ERF awards are intended for states/territories that demonstrate the need for additional resources to prevent, reduce, or eliminate ADAP waiting lists, including through cost-containment measures (for example, the provision of health insurance assistance).

HIV-Focused Population Surveys in Countries Supported Under the President's Emergency Plan for AIDS Relief (PEPFAR)

The primary purpose of this NOFO is to provide funding and technical assistance for HIV-focused, household-based surveys in national and subnational general populations of all ages in PEPFAR countries. The secondary purpose is for HIV-focused surveys and size estimation of key and priority populations in PEPFAR-supported countries. These activities serve to assess program impact to inform national and local responses to HIV, mostly located in sub-Saharan Africa.

Modeling and Simulation to Optimize HIV Prevention Research (MS OPR) (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support the development and validation of modeling and simulation methods and related tools to examine HIV transmission dynamics, make epidemic projections, and estimate the impact of HIV treatment and prevention. Investigators are expected to share these resources with other researchers. Funding for the final fourth year is dependent upon achieving applicant-proposed and pre-award negotiated "Go/No-Go criteria".

AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)

The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support an HIV/AIDS Research Center (ARC). The ARC is intended to provide infrastructural support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission.

Gastrointestinal Mechanisms Contributing to HIV Pathogenesis (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) seeks to bring together investigators with complementary expertise in HIV and in gastrointestinal mucosal pathobiology to dissect fundamental processes within the gastrointestinal tract that impact HIV infection, persistence, and comorbidities. This multidisciplinary approach should lead to comprehensive, in-depth mechanistic analyses and advance progress toward alleviating comorbidities that afflict people living with HIV and toward developing a cure.

Sustained Release Innovation for HIV (SRI) (R61/R33 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires communication with/ pre-IND submission to the FDA.

Pages

Subscribe to RSS - HIV/AIDS